Surendra Nayak
About Surendra Nayak
Surendra Nayak is the Scientific Associate Director at Bristol Myers Squibb in San Diego, California, with extensive experience in drug discovery and cancer therapeutics.
Company
Surendra Nayak is currently employed at Bristol Myers Squibb as Scientific Associate Director. Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. Surendra's role is based in San Diego, California, United States.
Title
Surendra Nayak holds the position of Scientific Associate Director at Bristol Myers Squibb. In this role, he leads drug discovery teams and projects focused on identifying cancer therapeutic candidates.
Education and Expertise
Surendra Nayak earned his Ph.D. in Biochemistry from the National Institute of Immunology, where he studied from 1994 to 1999. He has extensive experience in the use of various drug discovery modalities, including CELMoD, PROTAC, and ADC. He has been involved in numerous research publications in the field of cancer therapeutics, with a significant number of citations on Google Scholar, highlighting his impact in the scientific community.
Background
Surendra Nayak has an extensive background in the pharmaceutical and biotechnology industries. Before his current role, he worked as Senior Principal Scientist, Principal Scientist, and Senior Scientist at Bristol Myers Squibb from 2019 to 2023. Prior to that, he worked at Celgene, SRI International, Exelixis, Encysive Pharmaceuticals, and the Genomics Institute of the Novartis Research Foundation in various scientific and research roles. His career began with a postdoctoral fellowship at The University of Texas Southwestern Medical Center at Dallas from 1999 to 2003.
Mentorship and Leadership
Throughout his career, Surendra Nayak has taken on mentorship and leadership roles. He has successfully led drug discovery teams and projects and has mentored junior scientists and researchers in the field of drug discovery. His leadership extends to his contributions to research, which have been widely cited and recognized in the scientific community.